נועם דננברג מנכ"ל וייז פארמה – כנס ISCT
ממוצע זמן קריאה: 2 דקותWize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that Bonus BioGroup (TASE: BONS.TA), a company in which Wize owns an 8.9% equity stake, will present its scientific findings for MesenCure in the treatment of …